Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Feb 11 | 2025Novo Warns Against Compounders; Arrowhead (FY Q1 ‘25) and Vertex CY Q4 ‘24 Earnings; Oramed Enters Agreement for Oral InsulinPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 10 | 2025Lilly and OliX Partner in MASH; Hims & Hers Super Bowl Ad Controversy; Novartis Initiates Pelacarsen/Inclisiran Trial in Lp(a)Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 07 | 2025Ozempic CKD Label and Website AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 06 | 2025Orforglipron Takes Center Stage; Lilly Q4 ’24 Earnings CallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Feb 06 | 2025AZ and Viking Q4 ’24 EarningsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, Topics Feb 05 | 2025Questions Remain for Cagrisema Future; Novo Q4 ‘24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 04 | 2025Amgen, Pfizer, Merck, Regeneron Q4 ‘24 Earnings; Abbott Creates Diabetes FilmPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 03 | 2025Finerenone in HF Filed in EU; D&D Completes MASH Trial EnrollmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jan 31 | 2025Novartis and Biocon Q4 ’24 Earnings; Metsera and Beta Bionics IPO Updates; Fractyl Business UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jan 30 | 2025Roche and Sanofi Q4 ‘24 Earnings; Tectonic Interim Ph1b HFpEF DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 29 | 2025FDA Issues Warning Letter to Compounder; Lilly Discontinues HFpEF and CKD Asset; Teva Q4 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, Topics Jan 28 | 2025Ozempic Approved in CKD; Metsera Targets IPO Valuation; Helicore Launches as Obesity Company; Hims & Hers Super Bowl DTC; BioAge Scraps Azelaprag Program; Novo Caps Insulin PricesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, SGLT2i, Topics Jan 27 | 2025Akero Wins with F4 MASH Endpoint; Semaglutide + Enobosarm Combination Data; January 2025 CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 24 | 2025Novo Wins with Amycretin Ph1/2 Data; Another Obesity IPO; Allurion Gastric Balloon+GLP-1RA TrialPurchase Blast
$599
Posted in: Insulin Delivery, Topics Jan 23 | 2025Beta Bionics Set to IPO with $635M ValuationPurchase Blast
$599
Posted in: ESPR, Glucose Monitoring, Other, Topics Jan 22 | 2025Abbott Q4 ‘24 Earnings; Esperion KOL EventPurchase Blast
$599
Posted in: Other, Topics Jan 21 | 2025FDA Accepts Plozasiran NDA for FCS; Cytokinetics Opens Ph2 AMBER-HFpEF Trial EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 17 | 2025Sema on Medicare Negotiation List; STEP UP Topline Results; Long-Term Cagrisema Trial; EMA Reviewing Sema for NAION RiskPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jan 16 | 2025JPM 2025 Day 4: SKYE, ESPR, TRNS, IVAPurchase Blast$599
Posted in: Allogeneic, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 15 | 2025JPM 2025 Day 3: PODD, MDGL, BMEA, IONS, SANA; Novo Wins PRV; Mounajro DTC; Lexaria Oral Liraglutide; Wisp Sublingual SemaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
